💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Dolutegravir Sodium

CHEMBL1213165 Phase 4 승인됨 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
441.4 g/mol
LogP
—
Phase
4

The sodium salt form of dolutegravir, used in some pharmaceutical preparations of this integrase inhibitor for HIV treatment. As the parent drug dolutegravir, it prevents HIV from inserting its genetic material into human cell DNA. This salt form may be used to optimize solubility and bioavailability in specific formulations.

분자량

441.4000 g/mol

TPSA

102.00 Ų

치료 영역

Cardiovascular Disease Rheumatoid Arthritis Osteoporosis Generalized Anxiety Disorder Insomnia Non-Alcoholic Fatty Liver Disease Obesity Malaria HIV/AIDS Hepatitis C Tuberculosis Heart Failure

작용 기전

Inhibits viral integrase, preventing the insertion of viral DNA into the host cell genome and blocking viral replication.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Inhibits viral integrase, preventing the insertion of viral DNA into the host cell genome and blocking viral replication.

2D 구조

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c([O-])c3C(=O)N12.[Na+]

                

                

                
                

                    
InChI

                    
InChI=1S/C20H19F2N3O5.Na/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22;/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28);/q;+1/p-1/t10-,15+;/m1./s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C20H18F2N3NaO5

                    

                    
                    

                        
HBD / HBA

                        
1 / 8

                    

                    
                    

                        
회전 가능 결합

                        
3

                    

                    
                    
                    

                        
무거운 원자

                        
31

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
자주 묻는 질문

                

                    
                    

                        
                        

                            
The sodium salt form of dolutegravir, used in some pharmaceutical preparations of this integrase inhibitor for HIV treatment. As the parent drug dolutegravir, it prevents HIV from inserting its genetic material into human cell DNA. This salt form may be used to optimize solubility and bioavailability in specific formulations.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits viral integrase, preventing the insertion of viral DNA into the host cell genome and blocking viral replication.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Dolutegravir Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1213165.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 46216142.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
의학적 면책조항

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.